Juraj Vozár, Miriam Avramovová, Viera Doničová, Adriana Ilavská, Peter Jackuliak, Ingrid Jurkovičová, Boris Krahulec, Lujza Štrbová, Eva Tošerová, Martina Chlebcová
In the retrospective analysis we analysed 77 patients with type 2 diabetes mellitus treated with liraglutide in median 12 (min. 6 - max. 24) months. The patients were treated with oral antidiabetic mono, bi- or tritherapy. The age median was 55.5 years and duration of diabetes was 7.7 years. We recorded statistically high significant decrease of fasting blood glucose from 9.3 mmol/l (8.9 - 10) and HbA1c from 8.6 % (8.2 - 8.7) at the beginning of the study to 7.6 mmol/l (6,5 - 8,3) resp. 7.6 % (7.4 - 7.9) % after 12- month follow up (p < 0.001). Similarly, we recorded statistically high significant decrease of weight and body mass index from 102 kg (99 - 112) kg resp. 35.4 kg/m2 (33.7 - 36.3) basal to 98 kg (93 - 103) resp. 33.8 kg/m2 (32,1 - 35,9) after 12- month of treatment (p < 0.001). Lipid parameters were improved at the end of follow up but statistically not significantly. Blood pressure did not change during the 12 months of follow up. The median dose of liraglutide was 1.2 mg/day (1 - 1.5) after 12 months. The incidence of gastrointestinal adverse events occurred temporarily in 15 (20 %) patients and three of them finished the treatment due to that reason. Hypoglycaemia appeared in one patient and disappeared after sulfonylurea secession. Four patients (5 %) finished their treatment due to the high drug supplementary charge. Eleven (14.3 %) patients finished their treatment due to insufficient efficacy on HbA1c levels. The treatment with liraglutide continued successfully in 57 of 77 patients (74 %).